December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet Franklin Medal in Chemistry from The Franklin Institute yesterday for contributions to the field of mass

November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd

Chemistry, former president of the Royal Society of Chemistry and Founder of (and ongoing consultant to) OMass Therapeutics, which is based at Oxford Science Park, has been awarded the 2022 Louis-Jeantet Prize for

signaling shifts across a lifetime, and how high dimensional data turns biological complexity into therapeutic His current work combines mass spectrometry, natural language processing and topological data analysis to build GPCR based therapeutics that act on the gerontological roots of disease, a research stream versus high dimensionality biology, from one band on a western blot to eighteen thousand proteins on a mass More dimensions of signaling means more places a therapeutic can enter.

Her work employs X-ray crystallography, single-particle cryo-EM, mutagenesis, and mass spectrometry, mutations in the GABA-B transmembrane domain and what they suggest about precision pharmacology The therapeutic Using mass spectrometry in collaboration with colleagues at UC Davis, they identified the exact molecular But its therapeutic window is narrow.

Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They shared their unconventional approaches to research, including the creation of a critical mass of Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic